Denova-Gutiérrez Edgar, Lara-Castor Laura, Hernández-Alcaraz Cesar, Hernández-Ávila Mauricio, Aguilar-Salinas Carlos, Kershenobich David, Barquera Simón
Nutrition and Health Research Center, National Institute of Public Health, Cuernavaca, Mexico.
Nutrition and Health Research Center, National Institute of Public Health, Cuernavaca, Mexico; Friedman School of Nutrition Science and Policy, Tufts University, Boston, USA.
Ann Hepatol. 2021 Dec;26:100562. doi: 10.1016/j.aohep.2021.100562. Epub 2021 Oct 13.
To determine the prevalence of elevated liver enzyme levels and the fatty liver index according to specific sociodemographic, clinical, anthropometric, and metabolic risk factors in Mexican adult population.
The present analysis was conducted using data from the Mexican National Health and Nutrition Survey 2016. For the present study, 3,490 adults with complete information on liver enzymes, sociodemographic, lifestyle, and metabolic factors were analyzed. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) levels were determined from blood samples. We computed the fatty liver Index (FLI), as a surrogate marker of non-alcoholic fatty liver disease. The associations are reported as adjusted odds ratios (OR) and 95% confidence intervals (95%CI).
At the national level, the prevalence of high serum levels of ALT, AST, and GGT were 7.9%, 13.5, and 12.9 respectively. We observed that men had higher prevalences of altered ALT, GGT and FLI compared to women. Additionally, we observe that individuals with obesity, metabolic syndrome and insulin resistance are significantly more likely to present elevated concentrations of AST, ALT, GGT and FLI. Finally, we found that the subjects of the lowest socioeconomic level and indigenous population were more likely to present elevated levels of AST, ALT, GGT, and FLI.
In Mexico, non-alcoholic fatty liver disease affect people with obesity, diabetes, and metabolic syndrome as well as men, subjects of low socioeconomic status, subjects who live in rural areas and indigenous population. Interventions to reduce this condition should be a public health priority.
根据特定的社会人口学、临床、人体测量学和代谢风险因素,确定墨西哥成年人群中肝酶水平升高和脂肪肝指数的患病率。
本分析使用了2016年墨西哥国家健康与营养调查的数据。在本研究中,对3490名拥有肝酶、社会人口学、生活方式和代谢因素完整信息的成年人进行了分析。从血样中测定丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)和γ-谷氨酰转移酶(GGT)水平。我们计算了脂肪肝指数(FLI),作为非酒精性脂肪性肝病的替代标志物。关联结果以调整后的优势比(OR)和95%置信区间(95%CI)报告。
在国家层面,血清ALT、AST和GGT高水平的患病率分别为7.9%、13.5%和12.9%。我们观察到,与女性相比,男性ALT、GGT和FLI异常的患病率更高。此外,我们观察到肥胖、代谢综合征和胰岛素抵抗个体的AST、ALT、GGT和FLI浓度显著升高的可能性更大。最后,我们发现社会经济水平最低的人群和原住民更有可能出现AST、ALT、GGT和FLI水平升高。
在墨西哥,非酒精性脂肪性肝病影响肥胖、糖尿病和代谢综合征患者,以及男性、社会经济地位低的人群、农村地区居民和原住民。减少这种疾病的干预措施应成为公共卫生的优先事项。